- Home
- Companies
- ScreenPoint Medical
- Products
- ScreenPoint - Diagnosis of Breast ...
ScreenPoint - Diagnosis of Breast Cancer Technology
The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer. “Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments. “But we always remember that our excellence in innovation must be matched by the way we run our business. We are lean, focused on producing optimum results with cost savings passed on to our customers.”
Co-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction:
“I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable. So I decided to move away from robotics and concentrate on the analysis of breast scans.’
My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours.
I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.
Both of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer.
In 2014 we started ScreenPoint Medical. We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency.
There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide.
ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. Transpara is the world leader!”